Acceleron Pharma
128 Sidney Street
Cambridge
Massachusetts
United States
412 articles about Acceleron Pharma
-
Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021
7/26/2021
Acceleron Pharma Inc. announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second quarter 2021 financial results.
-
The FDA has historically tended to keep more contentious relationships with some companies private. But recently, the agency appears to be publicly scolding some biopharma companies.
-
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
6/11/2021
Bristol Myers Squibb and Acceleron Pharma Inc. announced the first data from the Phase 2 BEYOND study evaluating Reblozyl®, a first-in-class erythroid maturation agent, plus best supportive care in adult patients with non-transfusion dependent beta thalassemia, were presented at the European Hematology Association 2021 Virtual Congress as part of its Presidential Symposium.
-
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
-
Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021
6/8/2021
Acceleron Pharma Inc. today announced it will host a Virtual R&D Day for analysts and investors on June 22, 2021. The virtual event will take place from 8:00 a.m.
-
Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference
5/19/2021
– Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and in other diseases – - Company-hosted investor and analyst conference call and webcast with guest PAH key opinion leader to be held today, Wednesday, May 19th at 10:30 a.m. EDT –
-
Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept
5/19/2021
- Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotatercept plus stable background therapy for up to 48 weeks - - Patients receiving placebo plus stable background therapy during the 24-week placebo-controlled period who were re-randomized to sotatercept plus stable background therapy during weeks 24 to 48 experienced improvements
-
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
-
Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress
5/12/2021
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that multiple abstracts on REBLOZYL® (luspatercept-aamt) will be presented at the upcoming 2021 European Hematology Association (EHA2021) Virtual Congress
-
Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) Presented at the American Thoracic Society (ATS) 2021 International Conference
5/11/2021
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast on Wednesday, May 19, 2021 at 10:30 a.m.
-
Acceleron Reports First Quarter 2021 Financial Results
5/6/2021
REBLOZYL, the first and only erythroid maturation agent, was approved by Health Canada for the treatment of transfusion-dependent anemia in adults with myelodysplastic syndromes (MDS)
-
Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales
4/29/2021
Acceleron Announces First Quarter 2021 REBLOZYL ® Net Sales - Acceleron expects to report approximately $22.4 million in royalty revenue for Q1 2021 from approximately $112 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb -
-
The FDA is threatening Acceleron with a $10,000 fine or criminal prosecution, charging the company with failure to post a summary of study data on its cancer combo dalantercept and axitinib in the ClinicalTrials.gov online database.
-
Acceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021
4/26/2021
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results.
-
Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society (ATS) 2021 International Conference
4/5/2021
Conference to include interim results from the open-label extension of the PULSAR Phase 2 trial showing consistent or improved responses in efficacy endpoints among sotatercept-treated patients
-
New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension
4/1/2021
New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension – Results show patients treated with sotatercept experienced improvements in hemodynamic and functional endpoints compared with placebo –
-
Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results
2/25/2021
Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions
-
Acceleron to Participate in Two Upcoming Healthcare Investor Conferences - Feb 23, 2021
2/23/2021
Acceleron Pharma Inc., a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that senior management will participate in two upcoming virtual healthcare investor conferences.
-
Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
2/17/2021
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth quarter and full year 2020 financial results.
-
Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes
2/16/2021
REBLOZYL®, an erythroid maturation agent, is the first and only of its kind approved for use in Canada